HighTower Advisors LLC Purchases 126,927 Shares of Certara, Inc. (NASDAQ:CERT)

HighTower Advisors LLC grew its position in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 647.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 146,539 shares of the company's stock after purchasing an additional 126,927 shares during the quarter. HighTower Advisors LLC owned about 0.09% of Certara worth $1,561,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of CERT. Brown Brothers Harriman & Co. acquired a new stake in Certara during the third quarter worth approximately $27,292,000. Wasatch Advisors LP boosted its holdings in shares of Certara by 22.4% during the 3rd quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company's stock worth $105,577,000 after buying an additional 1,651,076 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Certara by 169.0% during the 4th quarter. Bank of New York Mellon Corp now owns 1,995,071 shares of the company's stock worth $21,248,000 after buying an additional 1,253,385 shares during the period. Massachusetts Financial Services Co. MA increased its stake in shares of Certara by 40.7% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company's stock valued at $45,691,000 after acquiring an additional 1,128,006 shares in the last quarter. Finally, Glenmede Trust Co. NA lifted its position in shares of Certara by 78.6% during the 3rd quarter. Glenmede Trust Co. NA now owns 1,206,069 shares of the company's stock valued at $14,123,000 after acquiring an additional 530,598 shares during the period. Institutional investors and hedge funds own 73.96% of the company's stock.

Remove Ads

Analyst Ratings Changes

A number of equities research analysts have commented on CERT shares. Barclays raised their price target on shares of Certara from $12.00 to $13.00 and gave the stock an "equal weight" rating in a report on Friday, February 28th. TD Cowen began coverage on Certara in a research report on Thursday, February 27th. They issued a "buy" rating and a $16.00 target price for the company. William Blair reissued a "market perform" rating on shares of Certara in a research note on Thursday, February 27th. Finally, Stephens restated an "overweight" rating and set a $17.00 price objective on shares of Certara in a report on Thursday, February 27th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $15.83.

Certara Stock Down 2.1 %

CERT traded down $0.21 during midday trading on Friday, reaching $9.91. 957,466 shares of the company were exchanged, compared to its average volume of 1,034,643. Certara, Inc. has a one year low of $9.41 and a one year high of $19.18. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The company's fifty day moving average price is $12.47 and its 200 day moving average price is $11.46. The company has a market cap of $1.60 billion, a price-to-earnings ratio of -49.55, a price-to-earnings-growth ratio of 9.29 and a beta of 1.60.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.